

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit:

BULLOCK ET AL.

Examiner:

APPLICATION NO: Unassigned

FILED: Herewith

Divisional of Serial No.: 09/468,663

Filed: December 21, 1999

FOR: ADDITIONAL THERAPEUTIC USE

Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to calculation of the filing fee, please enter the following amendment:

IN THE SPECIFICATION

On page 1, before the first paragraph, please insert the following:

--This is a divisional application of pending U.S. application Serial No. 09/468,663  
filed December 21, 1999--.

IN THE CLAIMS

Delete Claims 1-6.


Amend the following claims:

9. (Amended) A solid oral dosage form according to claim 7 comprising less than 13% of crosopvidone.
11. (Amended) A solid oral dosage form according to claim 7 comprising 20 to 65% of valsartan.

12. (Amended) A solid oral dosage form according to claim 7 comprising 20 to 360 mg of valsartan.

Add the following claims:

15. A method of treating obstructive airways diseases, wherein the diseases are selected from the group consisting of chronic obstructive pulmonary disease, adult respiratory distress syndrome, sepsis syndrome, pneumonia, aspiration of gastric content, chest trauma, shock, burns, fat embolia, cardiopulmonary bypass, O<sub>2</sub> toxicity, haemorrhagic pancreatitis, interstitial and bronchoalveolar inflammation comprising administering a therapeutically effective amount of valsartan of formula



to a patient in need thereof.

16. The method of claim 15 wherein chronic obstructive pulmonary disease includes bronchitis, chronic bronchitis, emphysema, asthma, cystic fibrosis, interstitial lung disease, pulmonary vascular disease and increased resistance to airflow during forced expiration.
17. A solid oral dosage form according to claim 8 comprising 20 to 65% of valsartan.
18. A solid oral dosage form according to claim 9 comprising 20 to 65% of valsartan.
19. A solid oral dosage form according to claim 10 comprising 20 to 65% of valsartan.
20. A solid oral dosage form according to claim 8 comprising 20 to 360 mg of valsartan.
21. A solid oral dosage form according to claim 9 comprising 20 to 360 mg of valsartan.

22. A solid oral dosage form according to claim 10 comprising 20 to 360 mg of valsartan.
23. A solid oral dosage form according to claim 11 comprising 20 to 360 mg of valsartan.
24. A solid oral dosage form according to claim 8 comprising less than 13% of crosopovidone.

#### STATUS OF THE CLAIMS

Claims 1-14 were present in the application.  
Claims 1-6 have been deleted.  
Claims 15-24 have been added.  
Claims 7-24 are presented for consideration.


#### REMARKS

This Preliminary Amendment is presented to add a parental data paragraph, to claim subject matter restricted from the parental application and to add additional claims which more completely define Applicants invention.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Respectfully submitted,

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6923  
Date: February 6, 2002

  
\_\_\_\_\_  
Gregory D. Ferraro  
Attorney for Applicants  
Reg. No. 36,134

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Amend the following claims:

9. (Amended) A solid oral dosage form according to claim 7 [or 8] comprising less than 13% of crospovidone.
11. (Amended) A solid oral dosage form according to [any one of claims 7 to 10] claim 7 comprising 20 to 65% of valsartan.
12. (Amended) A solid oral dosage form according to [any one of claims 7 to 11] claim 7 comprising 20 to 360 mg of valsartan.